Home / Stocks / ETON

ETON insider trading

Eton Pharmaceuticals, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
4
Bought · 24 mo
$1.1M
Buys · last 90 days
0 · $0
Most recent buy
2025-06-12

Recent insider filings

FiledInsiderTypeSharesPriceValue
2026-08-31MAIER PAUL V
Director
Sold36,387$58.64$2.1M
2026-08-28MAIER PAUL V
Director
Sold36,387$58.64$2.1M
2026-08-24Krempa David
Chief Business Officer
Sold25,000$65.07$1.6M
2026-08-20BRYNJELSEN SEAN
President & CEO
Sold83,680$60.58$5.1M
2026-07-07Opaleye Management Inc.
10% owner
Sold65,000$37.39$2.4M
2026-06-17Adams Jennifer McKie
Director
Sold50,000$32.48$1.6M
2026-05-29BRYNJELSEN SEAN
President & CEO
Sold119,852$31.88$3.8M
2026-05-27Krempa David
Chief Business Officer
Sold70,487$32.30$2.3M
2025-06-12Opaleye Management Inc.
10% owner
Bought7,930$15.82$125k
2025-06-05BRYNJELSEN SEAN
President & CEO
Sold200,945$17.05$3.4M
2024-10-25Opaleye Management Inc.
10% owner
Bought10,000$7.98$80k
2024-10-08Opaleye Management Inc.
10% owner
Bought62,070$6.99$434k
2024-09-12Opaleye Management Inc.
10% owner
Bought107,500$4.70$505k

Most active insider buyers

InsiderRoleBuysTotal bought
Opaleye Management Inc.10% owner4$1.1M

See ETON on the chart

Every insider buy and sell for ETON plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.